Chelsea understands what it takes to develop and deliver treatments
to patients and places a high value on collaborations with companies
and organizations whose strengths complement and augment our own.
We seek to work collaboratively with partners to supplement our product
pipeline, access complementary research and technology capabilities
and commercialize our therapeutic product candidates.
In the past year, Chelsea has formed multiple strategic alliances
to expand its pipeline including an in-licensing agreement with Dainippon
Sumitome Pharma Co., Ltd.
